<?xml version='1.0' encoding='utf-8'?>
<document id="22227917"><sentence text="Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits."><entity charOffset="13-25" id="DDI-PubMed.22227917.s1.e0" text="atorvastatin" /><entity charOffset="81-92" id="DDI-PubMed.22227917.s1.e1" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.22227917.s1.e0" e2="DDI-PubMed.22227917.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22227917.s1.e0" e2="DDI-PubMed.22227917.s1.e1" /></sentence><sentence text="Dyslipidemia is common in patients with type 2 diabetes" /><sentence text=" Statins are used as the first choice in treatment of diabetic dyslipidemia" /><sentence text=" Atorvastatin represents a first-line treatment option, alongside other hydroxyl methylglutaryl coenzyme A reductase inhibitors"><entity charOffset="1-13" id="DDI-PubMed.22227917.s4.e0" text="Atorvastatin" /></sentence><sentence text=" Repaglinide is a short-acting, oral, insulin secretagogue that is used in the treatment of type 2 diabetes mellitus"><entity charOffset="1-12" id="DDI-PubMed.22227917.s5.e0" text="Repaglinide" /></sentence><sentence text=" Both the category of drugs undergo extensive metabolism with cytochrome enzyme system" /><sentence text=" This may lead to drug-drug interaction problems with altered repaglinide activity which is cautious"><entity charOffset="62-73" id="DDI-PubMed.22227917.s7.e0" text="repaglinide" /></sentence><sentence text=" Repaglinide/atorvastatin/atorvastatin + repaglinide were administered orally to normal, diabetic rats, and to normal rabbits"><entity charOffset="1-12" id="DDI-PubMed.22227917.s8.e0" text="Repaglinide" /><entity charOffset="13-25" id="DDI-PubMed.22227917.s8.e1" text="atorvastatin" /><entity charOffset="26-52" id="DDI-PubMed.22227917.s8.e2" text="atorvastatin + repaglinide" /><pair ddi="false" e1="DDI-PubMed.22227917.s8.e0" e2="DDI-PubMed.22227917.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22227917.s8.e0" e2="DDI-PubMed.22227917.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s8.e0" e2="DDI-PubMed.22227917.s8.e2" /><pair ddi="false" e1="DDI-PubMed.22227917.s8.e1" e2="DDI-PubMed.22227917.s8.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s8.e1" e2="DDI-PubMed.22227917.s8.e2" /></sentence><sentence text=" Blood samples were collected at different time intervals and were analyzed for blood glucose by GOD-POD method using commercial glucose kits and repaglinide estimation in plasma by HPLC method"><entity charOffset="86-93" id="DDI-PubMed.22227917.s9.e0" text="glucose" /><entity charOffset="129-136" id="DDI-PubMed.22227917.s9.e1" text="glucose" /><entity charOffset="146-157" id="DDI-PubMed.22227917.s9.e2" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.22227917.s9.e0" e2="DDI-PubMed.22227917.s9.e0" /><pair ddi="false" e1="DDI-PubMed.22227917.s9.e0" e2="DDI-PubMed.22227917.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s9.e0" e2="DDI-PubMed.22227917.s9.e2" /><pair ddi="false" e1="DDI-PubMed.22227917.s9.e1" e2="DDI-PubMed.22227917.s9.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s9.e1" e2="DDI-PubMed.22227917.s9.e2" /></sentence><sentence text=" Diabetes was induced by alloxan 100 mg/kg body weight administered by I"><entity charOffset="25-32" id="DDI-PubMed.22227917.s10.e0" text="alloxan" /></sentence><sentence text="P route" /><sentence text=" In the presence of atorvastatin, repaglinide activity was increased and maintained for longer period in diabetic rats compared with repaglinide matching control"><entity charOffset="20-32" id="DDI-PubMed.22227917.s12.e0" text="atorvastatin" /><entity charOffset="34-45" id="DDI-PubMed.22227917.s12.e1" text="repaglinide" /><entity charOffset="133-144" id="DDI-PubMed.22227917.s12.e2" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.22227917.s12.e0" e2="DDI-PubMed.22227917.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22227917.s12.e0" e2="DDI-PubMed.22227917.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s12.e0" e2="DDI-PubMed.22227917.s12.e2" /><pair ddi="false" e1="DDI-PubMed.22227917.s12.e1" e2="DDI-PubMed.22227917.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s12.e1" e2="DDI-PubMed.22227917.s12.e2" /></sentence><sentence text=" The present study concludes co-administration of atorvastatin was found to improve repaglinide responses significantly in diabetic rats and improved glucose metabolism of atorvastatin played an important role and increased repaglinide levels by competitive CYP 3A4 enzyme inhibition by atorvastatin could be added advantage for anti hyperglycemic activity"><entity charOffset="50-62" id="DDI-PubMed.22227917.s13.e0" text="atorvastatin" /><entity charOffset="84-95" id="DDI-PubMed.22227917.s13.e1" text="repaglinide" /><entity charOffset="150-157" id="DDI-PubMed.22227917.s13.e2" text="glucose" /><entity charOffset="172-184" id="DDI-PubMed.22227917.s13.e3" text="atorvastatin" /><entity charOffset="224-235" id="DDI-PubMed.22227917.s13.e4" text="repaglinide" /><entity charOffset="287-299" id="DDI-PubMed.22227917.s13.e5" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e0" e2="DDI-PubMed.22227917.s13.e0" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e0" e2="DDI-PubMed.22227917.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e0" e2="DDI-PubMed.22227917.s13.e2" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e0" e2="DDI-PubMed.22227917.s13.e3" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e0" e2="DDI-PubMed.22227917.s13.e4" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e0" e2="DDI-PubMed.22227917.s13.e5" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e1" e2="DDI-PubMed.22227917.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e1" e2="DDI-PubMed.22227917.s13.e2" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e1" e2="DDI-PubMed.22227917.s13.e3" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e1" e2="DDI-PubMed.22227917.s13.e4" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e1" e2="DDI-PubMed.22227917.s13.e5" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e2" e2="DDI-PubMed.22227917.s13.e2" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e2" e2="DDI-PubMed.22227917.s13.e3" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e2" e2="DDI-PubMed.22227917.s13.e4" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e2" e2="DDI-PubMed.22227917.s13.e5" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e3" e2="DDI-PubMed.22227917.s13.e3" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e3" e2="DDI-PubMed.22227917.s13.e4" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e3" e2="DDI-PubMed.22227917.s13.e5" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e4" e2="DDI-PubMed.22227917.s13.e4" /><pair ddi="false" e1="DDI-PubMed.22227917.s13.e4" e2="DDI-PubMed.22227917.s13.e5" /></sentence><sentence text="" /></document>